Halozyme has expanded its portfolio of drug delivery technologies for a second time in a few months with the acquisition of Surf Bio for up to $400m.
AstraZeneca makes $15B bet on China to expand manufacturing and R&D
AstraZeneca, already one of the leading pharmaceutical companies in China, is extending its reach in the country that’s become a go-to place for drug R&D


